Oral small molecule GLP-1 receptor agonist
Orforglipron 3 mg oral once daily
ORFO_PO_3MG_QD
Related
- All doses pooled: Orforglipron tablet
- Orforglipron 12 mg oral once daily
- Orforglipron 36 mg oral once daily
- Orforglipron 6 mg oral once daily
- Orforglipron maximum tolerated dose tablet once daily
- Orforglipron 1 mg tablet once daily
- Orforglipron 14.5 mg tablet once daily
- Orforglipron 17.2 mg tablet once daily
- Orforglipron 0.8 mg tablet once daily
- Orforglipron 2.5 mg tablet once daily
- Orforglipron 5.5 mg tablet once daily
- Orforglipron 9 mg tablet once daily
- Orforglipron 24 mg oral once daily
- Orforglipron 45 mg oral once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.76 (-1.26 to -0.25) | 0.29 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.06 (-1.96 to 0.09) | 0.37 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -2.64 (-5.25 to 0.06) | 0.29 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -2.93 (-7.07 to 2.45) | 0.40 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 4.16 (0.47 to 14.50) | 0.25 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 5.33 (1.14 to 15.58) | 0.68 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -2.37 (-4.91 to 0.17) | 0.50 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.19 (-7.15 to 2.76) | 0.42 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -3.17 (-9.70 to 3.84) | 0.34 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.63 (0.75 to 6.79) | 0.33 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD -0.21 (-1.22 to 0.82) | 0.35 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.31 (0.73 to 2.36) | 0.35 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.50 (2.28 to 5.34) | 0.39 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.58 (1.41 to 4.68) | 0.52 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.36 (1.62 to 3.42) | 0.31 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.37 (2.10 to 5.44) | 0.21 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 1.59 (0.08 to 24.33) | 0.36 |
Trials
- ACHIEVE-5A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor2023 · 546 randomized · 40 weeks
- ACHIEVE-1A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone2023 · 559 randomized · 40 weeks
- NCT05048719A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus2021 · 383 randomized · 26 weeks